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Coronary Physiologic Assessment and Imaging
Background—Fractional flow reserve (FFR) is not firmly established as a guide to treatment in patients with acute coronary 
syndromes (ACS). Primary goals were to evaluate the impact of integrating FFR on management decisions and on clinical 
outcome of patients with ACS undergoing coronary angiography, as compared with patients with stable coronary artery 
disease.
Methods and Results—R3F (French FFR Registry) and POST-IT (Portuguese Study on the Evaluation of FFR-Guided 
Treatment of Coronary Disease), sharing a common design, were pooled as PRIME-FFR (Insights From the POST-IT 
and R3F Integrated Multicenter Registries - Implementation of FFR in Routine Practice). Investigators prospectively 
defined management strategy based on angiography before performing FFR. Final decision after FFR and 1-year clinical 
outcome were recorded. From 1983 patients, in whom FFR was prospectively used to guide treatment, 533 sustained 
ACS (excluding acute ST-segment–elevation myocardial infarction). In ACS, FFR was performed in 1.4 lesions per 
patient, mostly in left anterior descending (58%), with a mean percent stenosis of 58±12% and a mean FFR of 0.82±0.09. 
In patients with ACS, reclassification by FFR was high and similar to those with non-ACS (38% versus 39%; P=NS). 
The pattern of reclassification was different, however, with less patients with ACS reclassified from revascularization to 
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Fractional flow reserve (FFR)–guided revascularization has been shown to be superior to angio-guided percutaneous 
coronary intervention (PCI) or coronary artery bypass graft-
ing (CABG) in reducing both short- and long-term major car-
diovascular events (MACEs; including death and myocardial 
infarction)1,2 and deferral of nonischemic lesions is associated 
with excellent outcomes.3 Several studies that have included 
mostly stable patients have suggested that routine use of FFR 
is associated with a high rate of reclassification and change in 
management decisions (up to 44%) and that treatment real-
location (against angiography) is safe.4–8
Patients sustaining an acute coronary syndrome (ACS) 
currently make up the majority of patients considered for coro-
nary revascularization.9 Invasive management of patients with 
ACS, including coronary angiography and revascularization 
(when needed), is the one situation where a potential mortal-
ity benefit has been demonstrated.10 Still, there is a clear need 
to further optimize clinical decision making in this important 
patient subset.
Concerns about microcirculatory responsiveness during the 
acute setting have undermined the use of FFR in patients with 
ACS.11 Although dedicated physiological studies have demon-
strated that measurement of FFR can be relevant in the context 
of ACS,12–14 clinical evidence supporting it’s use, particularly in 
the setting of non–ST-segment–elevation myocardial infarction 
(NSTEMI), is based on the results of relatively small clinical 
outcome studies and subgroup analysis.7,15 In addition, there is 
currently no report of the impact of routine use of FFR in the 
decision-making process in patients with ACS. Large studies, 
powered for clinical outcomes, are therefore needed to assess 
the integration of routine FFR measurement into the manage-
ment of patients with ongoing or recent ACS.
In addition to dedicated randomized trials,2,16 large nation-
wide studies, such as R3F and POST-IT,6,17 have contributed 
to deciphering how FFR can be integrated into patient man-
agement and impact clinical outcomes and have been of major 
importance for the implementation of FFR in clinical prac-
tice. In the large multicenter PRIME-FFR joint international 
prospective study (POST-IT and R3F Integrated Multicenter 
Registries - Implementation of FFR in Routine Practice),6,17 we 
aimed to assess the extent of treatment change by routine use 
of FFR in patients with ACS and the safety of reclassification 
and revascularization deferral as compared with stable patients.
Methods
Patient Population
The total population (n=1983) results from the merge of the R3F and 
the POST-IT cohorts.6,17 These nationwide prospective studies share a 
common design and objective, dedicated to investigate the routine use 
of FFR at the time of diagnostic angiography and its impact on patient 
management decisions and on 1-year clinical outcome. Specifically, 
the R3F study included 1075 consecutive patients with at least 1 angio-
graphically ambiguous lesion (35%–65% by visual estimate) in a ma-
jor epicardial coronary vessel evaluated by FFR in 20 French centers 
(October 2008 to June 2010). Similarly, the POST-IT study included 
918 patients at 19 Portuguese centers (March 2012 to November 
2013) and was designed to prospectively include all consecutive pa-
tients referred for angiography in whom at least 1 intermediate lesion 
at a major epicardial coronary vessel was evaluated by FFR.
In both studies, baseline, clinical, and angiographic parameters were 
prospectively recorded in an electronic case report form. Relevant in-
stitutional review boards and ethics committees approved the research 
WHAT IS KNOWN
• In patients with stable coronary artery disease, frac-
tional flow reserve (FFR) has been shown to change 
the revascularization decision in up to 44% of pa-
tients, whereas FFR-guided revascularization deci-
sion has been shown to improve clinical outcomes 
and reduce costs.
• The value of FFR-guided revascularization decision 
in patient with acute coronary syndrome (ACS) re-
mains unclear.
WHAT THE STUDY ADDS
• In patients with ACS, FFR is associated with a high 
rate of change of the revascularization strategy 
(38%), as high as in patients with non-ACS.
• In patients with ACS, integrating FFR information 
to reclassify patient management is safe, and, in par-
ticular, FFR-based deferral to medical treatment is as 
safe as it is in patients with non-ACS.
• In patients with ACS, disregarding the information 
derived from FFR is associated with a dire outcome.
medical treatment compared with those with non-ACS (P=0.01). In ACS, 1-year outcome of patients reclassified based 
on FFR (FFR against angiography) was as good as that of nonreclassified patients (FFR concordant with angiography), 
with no difference in major cardiovascular event (8.0% versus 11.6%; P=0.20) or symptoms (92.3% versus 94.8% angina 
free; P=0.25). Moreover, FFR-based deferral to medical treatment was as safe in patients with ACS as in patients with 
non-ACS (major cardiovascular event, 8.0% versus 8.5%; P=0.83; revascularization, 3.8% versus 5.9%; P=0.24; and 
freedom from angina, 93.6% versus 90.2%; P=0.35). These findings were confirmed in ACS explored at the culprit lesion. 
In patients (6%) in whom the information derived from FFR was disregarded, a dire outcome was observed.
Conclusions—Routine integration of FFR into the decision-making process of ACS patients with obstructive coronary 
artery disease is associated with a high reclassification rate of treatment (38%). A management strategy guided by FFR, 
divergent from that suggested by angiography, including revascularization deferral, is safe in ACS.  (Circ Cardiovasc 
Interv. 2017;10:e004296. DOI: 10.1161/CIRCINTERVENTIONS.116.004296.)
Key Words: acute coronary syndrome ◼ coronary artery disease ◼ coronary angiography  
◼ fractional flow reserve ◼ mortality
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protocols. All patients provided written informed consent for clinical 
follow-up and for both storage and use of their clinical data.
Management Strategy, Reclassification, and 
Deferral Definitions
As part of the e-CRF, investigators were asked to define prospectively 
their a priori management strategy for each patient, based on angi-
ography and available clinical information before FFR measurement 
and then, after FFR was performed, to define their final strategy. The 
use (or not: disregarded) of the FFR information to achieve the final 
management decision was also prospectively recorded.
This decision could be medical therapy (with or without additional 
stress test), PCI, or CABG. Patients in whom a hybrid approach was 
chosen were classified as CABG. When a final decision of revascular-
ization was reached for the patient, it could be performed immediate-
ly (PCI) or at later stage (PCI or CABG). Reclassification of patient 
management strategy was defined as a difference (or discordance) be-
tween the a priori and the final strategies. Revascularization deferral 
was identified when the final strategy was medical treatment for all 
lesions after performing the FFR measurement (no revascularization 
performed or planned).
Detailed Objectives
The primary objective was to describe and evaluate the safety of rou-
tine FFR use in patients with ACS undergoing diagnostic coronary 
angiography disclosing at least 1 visually intermediate lesion. In par-
ticular, we aimed to
1. describe the rate of reclassification of the patient management 
strategy and to evaluate the safety of such reclassification. For 
that purpose, we compared the occurrence of 1-year MACE ac-
cording to the agreement or divergence of the FFR-guided final 
decision with the a priori strategy suggested by angiography 
and 
2. describe the rate of revascularization “deferral” and to evalu-
ate its safety by comparing the occurrence of 1-year MACE in 
ACS-deferred patients versus “ACS-revascularized” and “non-
ACS-deferred” patients.
Secondary analyses aimed at evaluating (1) the impact of reclassifica-
tion and deferral on angina status at 1-year follow-up; (2) the outcome 
of patients in whom the results of FFR measurement were disregard-
ed by the investigators for deciding the final management strategy; 
and (3) the consistency of the primary objective in (a) patients with 
ongoing NSTEMI/UA (unstable angina) (which represent the most 
acute patients in our study population) and (b) in those investigated at 
the culprit vessel; this was done by focusing on patients with single-
vessel disease ACS because this is the only clinical situation in which 
the culprit nature of the investigated vessel can be ascertained.13
Definition of ACS and Recording of Baseline 
Characteristics
The presence of an ACS and classification as NSTEMI/UA or STEMI 
was defined at the time of inclusion according to current recommenda-
tions.18,19 More specifically, UA/NSTEMI was defined as the combina-
tion of at least 2 of the 3 following criteria: (1) chest pain, (2) troponin 
rise, or (3) ischemic ECG changes.18 Patients with NSTEMI/UA were 
classified as ongoing if the procedure was performed within 48 hours 
after symptom onset (typically within 24 hours of admission). After 
that, time window NSTEM/UA was classified as recent. Patients with 
STEMI undergoing primary PCI were not considered for enrollment 
in either R3F or POST-IT6,17 and thus were not represented in the final 
cohort. However, they could be included after the acute phase as recent 
ACS, typically if a nonculprit lesion was being evaluated in a second 
procedure (see Methods in the Data Supplement for further details).
Angiography and FFR Procedure
Angiography was performed according to the standard practice. 
Qualitative description of the angiography, including the number of 
diseased vessels, American College of Cardiology/American Heart 
Association (ACC/AHA) lesion classification, and quantitative (ref-
erence diameter, percent stenosis, and length) description of the FFR-
investigated lesions was recorded.
FFR measurement was performed after recording of angiographic 
parameters, according to the local standard practice. FFR could be 
done using diagnostic or interventional catheters after injection of in-
tracoronary nitrate. Extensive FFR evaluation was not mandated per 
protocol, and investigators were left free to decide which vessels and 
lesions to interrogate. Hyperemia was achieved using high adenosine 
dose administered through either intracoronary bolus (≥100 µg) or 
intravenous infusion (140 µg/kg per minute).
Clinical Follow-Up and End Points
One-year clinical follow-up was recorded in all patients, and inde-
pendent monitoring was performed in both studies. Angina status 
was obtained at 12-month follow-up. The study primary end point 
(MACE) was a composite of all-cause death, myocardial infarc-
tion, or unplanned revascularization. Each individual end point was 
reviewed and adjudicated by an independent clinical event com-
mittee. Myocardial infarction was defined according to the third 
2012 ESC/ACCF/AHA/WHF (European Society of Cardiology/ 
American College of Cardiology Foundation/American Heart 
Association/World Heart Federation) universal definition of MI.20 
Revascularization was considered unplanned when it was not per-
formed or planned at the time of the index procedure. Thus, both 
elective staged PCI and elective CABG resulting from the index FFR 
evaluation were not considered as events.
Statistical Analysis
Before merging R3F and POST-IT into the PRIME-FFR data set, 
comparisons were made to verify that there were no major differences 
between the main baseline characteristics of study patients (including 
epidemiological, clinical, and angiographic characteristics and FFR) 
and in the 1-year clinical outcome of the 2 study cohorts, both overall 
and inside each subgroup (ACS and non-ACS). Also, to check for the 
consistency of the results, we replicated the POST-IT analysis on the 
3RF population and vice versa.
Continuous variables are presented as mean±SD. Discrete vari-
ables are presented as absolute numbers and percentages. For patient-
related characteristics, differences among groups were evaluated 
using Student t test or χ2 test, as appropriate. The initial and final 
management strategy (medical therapy, PCI, and CABG) and over-
all decision to reclassify were evaluated using Fisher exact test. FFR 
was compared between ACS and non-ACS according to lesion ste-
nosis severity. For that purpose, stenosis severity was stratified into 4 
groups based on prespecified ranges and FFR values in each stratifi-
cation group were compared using the Wilcoxon rank-sum test.
Cumulative rates of MACE were estimated using the Kaplan–
Meier method, and differences between strategies were tested using 
Cox proportional hazards model. Multivariable Cox proportional haz-
ards models were performed adjusting for baseline clinical and an-
giographic characteristics. Multiple imputation was used to account 
for missing covariate data in the Cox proportional hazards models. 
A standard imputation model with discriminant function created 10 
imputed data sets for each model. The Cox model was applied to each 
imputed data set. Final summary results were produced by pooling 
the individual proportional hazards estimates, accounting for the SE 
within and between the models. Additional details are provided in the 
Methods in the Data Supplement. Analyses were conducted using the 
SAS system (SAS v9.4; SAS Institute, Cary, NC).
Results
Clinical Characteristics
Study population included 1983 patients, of whom 533 (27%) 
underwent coronary angiography and routine FFR evaluation 
in the context of an ACS (Table 1; Figure 1). Among patients 
with ACS, 43% had an ongoing NSTEMI/UA, 40% a recent 
NSTEMI/UA, and 17% a recent STEMI. These patients with 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6  Van Belle et al  Routine FFR for Clinical Management in ACS 
ACS had a typical clinical profile of such a population; when 
compared with patients with non-ACS, they were younger, 
more likely smokers, but less likely to have conventional risk 
factors (Table 1). They also had a more frequent history of 
previous ACS and were more likely to be treated with dual 
antiplatelet therapy at the time of angiography.
FFR and Angiographic Characteristics
In patients with ACS, single-vessel (0–1) and multivessel (2–
3) angiographically defined coronary artery disease (CAD) 
were observed in 53% and 47%, respectively. FFR was per-
formed in 1.4 lesions per patient (≥2 lesions in 27%). Overall, 
intracoronary adenosine was used in 54.3% of the evaluations 
(and conversely, the systemic intravenous route was used in 
the remainder). The investigated lesion was located on the 
left anterior descending artery in 58% of cases and was proxi-
mally located in 33% of cases. Mean percent diameter stenosis 
was 57% by visual estimate, and it was a typical intermediate 
lesion (<70% stenosis) in three fourth of cases (Table 2).
Lesions investigated in patients with ACS were slightly 
(but not significantly) more severe on angiographic appear-
ance (proportion of lesions ≥70% by visual estimate: 22.8% 
versus 19.9%; P=0.10; Table 2) and definitely more com-
plex than in patients with non-ACS (B2/C: 42% versus 38%; 
P=0.02; Table 2). Mean FFR (0.82±0.09 versus 0.82±0.10; 
P=0.76; Table 2; Figure 2A and 2C) and the relationship 
between angiographic percent stenosis severity and FFR 
were similar between patients with ACS and non-ACS 
(Figure 2C; Figure I in the Data Supplement). Importantly, 
within each category of stenosis severity, FFR was lower in 
more complex lesions (B2/C versus A/B1; Table I in the Data 
Supplement). Consistent with this observation, multivariable 
analyses of clinical and angiographic parameters associated 
with the FFR value identified the same predictors in patients 
with both ACS and non-ACS: age, left anterior descending 
location, ACC/AHA lesion type, percent stenosis, lesion 
length, and number of diseased vessels (Table II in the Data 
Supplement).
ACS Status and Clinical Outcome
In the overall ACS population, regardless of FFR result and 
FFR-based decision, the rates of MACE and of death/MI at 1 
year were 10.9% and 6.8%, respectively, which were higher 
than in the non-ACS group (9.5% and 3.2%, with P=0.34 and 
P<0.01, respectively). The proportion of patients free from 
angina at 1 year was similar in patients with ACS and non-
ACS (93% versus 91%; P=0.45).
FFR-Based Reclassification of the Management 
Strategy
In the vast majority of procedures (94%; n=1869), physicians 
used the information provided by FFR to drive their final 
management decision. The proportion of cases where FFR 
was used for decision was similar in patients with ACS and 
non-ACS (Figure 1; Table 1). In these patients, the overall rate 
of FFR-based reclassification of treatment strategy was simi-
lar in ACS and non-ACS (38% versus 39%; P=0.55; Table 1; 
Figure 3A). However, as illustrated in Table 1, Figure 3B and 
3C, and Figure II in the Data Supplement, the reclassification 
pattern diverged significantly between patients with ACS and 
non-ACS. Reclassification resulted in an increase in the pro-
portion of patients who were revascularized in both subgroups, 
but significantly more so in the ACS population (+26% versus 
+7%; P=0.03). Consequently, relative to baseline decision, the 
proportion of patients submitted to PCI or CABG after FFR 
was known (final decision) was higher in the ACS group than 
in the non-ACS group (51.1% versus 45.2%; P=0.02; Table 1; 
Figure II in the Data Supplement).
Baseline clinical and angiographic characteristics of the 
719 patients (n=188 ACS and n=531 non-ACS) in whom the 
use of FFR was associated with reclassification of the man-
agement strategy are presented in Tables 1 and 2. Although 
purely clinical characteristics were similar between reclassi-
fied and nonreclassified patients (Table 1), those reclassified 
were more likely to have 2- to 3-vessel CAD (P<0.001), an 
left anterior descending lesion (P<0.006), and a lower FFR 
value (P<0.001).
Figure 1. Study flow chart and safety of the fractional flow reserve (FFR)–based-reclassification the revascularization strategy according 
to acute coronary syndrome (ACS) status. The 1-y outcome of patients with ACS reclassified to a different strategy based on FFR (FFR 
discordant from angiography) was as good as in nonreclassified patients (FFR concordant with angiography) both in terms of major car-
diovascular event (MACE) and in the of proportion of patients angina free. MI indicates myocardial infarction.
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FFR-Based Reclassification of Management 
Strategy and Clinical Outcome in Patients With 
ACS
Among the 499 patients with ACS in whom FFR was used 
for decision, reclassification of the management strategy (ie, 
FFR-based decision discordant with angiography; n=188) 
was safe. These patients had a 1-year clinical outcome at 
least as good as in those (n=311) in whom the decision was 
not reclassified by FFR (ie, FFR-based decision concor-
dant with angiography): 1-year MACE rate of 8.0% versus 
11.6%, respectively (log rank P=0.20; Table 3; Figures 1 and 
4A). These findings were consistent irrespective of the ini-
tial revascularization strategy (Figure III in the Data Supple-
ment) and were not modified after multivariable adjustment 
(Table 4, analysis by ACS and reclassification status). A 
similar pattern was observed for the combined rate of death/
MI (4.3% versus 7.7%; log rank P=0.13), the rate of MI or 
unplanned coronary revascularization (Table 3), or the pro-
portion of patients free from angina at 1 year (92.3 versus 
94.8, P=0.25). As reported previously, reclassification of the 
management strategy was also safe in patients with non-ACS 
(Figures 1 and 3; Table 3).
FFR-Based Deferral of Revascularization in ACS: 
Patient Profile and Clinical Outcome
Among those in whom FFR was used to drive the final deci-
sion, patients with ACS were less frequently deferred to 
medical treatment (all lesions deferred) than patients with 
non-ACS (237/499 [47%] versus 721/1353 [53%]; P=0.01; 
Table 5). Deferred patients were older, but had less risk fac-
tors than those not deferred (Table III in the Data Supple-
ment). As expected, deferred patients were also less likely to 
have 2- to 3-vessel CAD (<0.01), an left anterior descending 
lesion (<0.01), angiographically complex disease (<0.01), and 
severe lesions (<0.01), while having a much high FFR value 
(P<0.001; Table IV in the Data Supplement).
Importantly, in the ACS cohort, FFR-based deferral identi-
fied a group of patients at lower risk of 1-year MACE (8.0%), 
as compared with the remainder of the ACS population. The 
rate of MACE in the former was lower than in nondeferred 
patients with ACS (12.3%; P=0.09; Table 5; Figure 4B) and 
of the same magnitude as in patients with non-ACS deferred 
(8.5%; P=0.83; Table 5; Figure 4B). These findings were con-
sistent after multivariable adjustment (Table 4, analysis by 
ACS and deferral status).
Figure 2. A, Fractional flow reserve (FFR) value distribution in the acute coronary syndrome (ACS) population. B, FFR value distribution in 
the non-ACS population. C, FFR value stratified by the stenosis severity group. A similar normal distribution of FFR values was observed 
in patients with both ACS and non-ACS. No difference in FFR value was observed between patients with ACS and non-ACS in each of 
the stratum of stenosis severity.
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FFR Disregarded: Patient Profile and Clinical 
Outcome
The baseline clinical and angiographic characteristics of the 
121 patients (ACS n=34 and non-ACS n=97; 6% of total pop-
ulation) in whom FFR data were not used for the final decision 
(FFR disregarded) are presented in Tables 1 and 2. Although 
clinical and angiographic characteristics were similar between 
the 2 groups (FFR disregarded versus FFR used), patients in 
whom FFR values were disregarded tended to have a higher 
proportion of lesions with FFR≤0.80 both in the ACS (50% 
versus 39.5%; P=0.2) and non-ACS (71.6% versus 37.9%; 
P<0.001) population.
In these 121 patients, the MACE rate at 1 year was twice 
as high as in the 1862 patients in whom the FFR information 
was used for final decision (23/121 [19%] versus 172/1862 
[9.2%]; P=0.0008). Similarly, patients in whom FFR was 
Figure 3. A, Overall rate of fractional flow reserve (FFR)–based reclassification of the revascularization strategy in patients with acute coronary 
syndrome (ACS) and non-ACS. B, Detailed description of the FFR-based reclassification of the revascularization strategy according to the 
revascularization strategy a priori in patients with ACS and non-ACS. For this illustration, 3 groups of revascularization strategy are considered: 
(1) medical treatment, (2) percutaneous coronary intervention (PCI), and (3) coronary artery bypass grafting (CABG). C, Identical to B with 2 
groups of a revascularization strategy considered: (1) medical treatment and (2) revascularization (PCI/CABG). MT indicates medical treatment.
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disregarded tended to have more angina at 1 year than those in 
whom FFR was used for the final decision (12% versus 7%; 
P=0.1). These findings were consistent across both ACS and 
non-ACS groups (Figure 1; Figure IV in the Data Supplement; 
Table 4, analysis by ACS and FFR usage).
FFR-Based Reclassification/Deferral and Clinical 
Outcome in Ongoing NSTEMI/UA and in Patients 
Investigated at the Culprit Vessel
Among patients with ACS (n=533), clinical outcome sub-
analyses were performed in 2 subgroups of interest that were 
identified according to study definitions: patients with an 
ongoing-NSTEMI/UA and those with single-vessel-CAD. 
The former is an important subgroup because it represents the 
most acute patients among our study population, whereas the 
latter is an even more important one because it is the only 
clinical situation in which the culprit nature of the investigated 
vessel can be ascertained.
The results in each of the 2 subpopulations—ongoing-
NSTEMI/UA and single-vessel CAD ACS (illustrative of 
patients investigated at the culprit vessel)—were consistent 
with the analysis performed in the whole ACS cohort. No 
heterogeneity was found in the trends of MACE, associated 
with either overall management reclassification or, specifically, 
revascularization deferral (P>0.5 for all interaction tests; Tables 
V and VI in the Data Supplement). Similar to the findings in the 
overall population, the analysis restricted to patients with sin-
gle-vessel CAD demonstrated that FFR-driven reclassification 
Table 3. Clinical Outcomes at 12 Months According to Clinical Presentation (ACS and Non-ACS) and FFR-
Driven Reclassification Status





ACS FFR used (n=499) 51 (10.2%) 32 (6.4%) 23 (4.6%) 13 (2.6%) 26 (5.2%)
  ACS maintained (n=311, 62%) 36 (11.6%) 24 (7.7%) 17 (5.5%) 11 (3.5%) 19 (6.1%)
  ACS reclassified (n=188, 38%) 15 (8.0%) 8 (4.3%) 6 (3.2%) 2 (1.1%) 7 (3.7%)
  P value (log rank) 0.20 0.13 0.24 0.11 0.24
Non-ACS FFR used( n=1353) 121 (9.0%) 42 (3.1%) 27 (2.0%) 16 (1.2%) 89 (6.6%)
  Non-ACS maintained (n=822, 61%) 72 (8.8%) 28 (3.4%) 17 (2.1%) 11 (1.3%) 52 (6.4%)
  Non-ACS reclassified (n=531, 39%) 49 (9.2%) 14 (2.6%) 10 (1.9%) 5 (0.9%) 37 (7.0%)
  P value (log rank) 0.77 0.42 0.82 0.51 0.64
Data represented as count (%); percentages based on patients with available data. ACS indicates acute coronary syndrome; FFR, 
fractional flow reserve; MACE, major cardiovascular event; and MI, myocardial infarction.




Multivariable Complete Case 
Only† Multiple Imputation‡
HR (CI) P Value HR (CI) P Value HR (CI) P Value
Analysis by ACS and reclassification status
  ACS (reclassified vs nonreclassified) 0.67 (0.37–1.23) 0.201 0.63 (0.34–1.16) 0.140 0.63 (0.34–1.16) 0.136
  Non-ACS (reclassified vs nonreclassified) 1.06 (0.73–1.52) 0.772 0.99 (0.68–1.46) 0.971 1.04 (0.72–1.51) 0.833
Analysis by ACS and deferral status
  ACS (all lesion deferred vs at least 1 
revascularization)
0.65 (0.37–1.14) 0.131 0.65 (0.35–1.23) 0.187 0.63 (0.34–1.19) 0.159
  Non-ACS (all lesion deferred vs at least 1 
revascularization)
0.89 (0.62–1.27) 0.514 0.97 (0.61–1.56) 0.907 0.88 (0.56–1.40) 0.596
  All lesions deferred (ACS vs non-ACS) 0.95 (0.57–1.58) 0.834 1.01 (0.60–1.69) 0.980 0.97 (0.58–1.62) 0.893
Analysis by ACS and FFR usage
  ACS (FFR disregarded vs FFR used) 2.10 (0.95–4.63) 0.065 2.00 (0.91–4.42) 0.087 2.01 (0.91–4.45) 0.084
  Non-ACS (FFR disregarded vs FFR used) 1.92 (1.14–3.23) 0.014 1.91 (1.13–3.23) 0.015 1.83 (1.09–3.09) 0.023
ACS indicates acute coronary syndrome; CI, confidence interval; FFR, fractional flow reserve; and HR, hazard ratio.
*Cox proportional hazards model without adjusting for baseline characteristics.
†Cox proportional hazards model controlling for baseline characteristics including for analysis by ACS and reclassification status: age, sex, history of 
diabetes mellitus, history of hypertension, high cholesterol, number of diseased vessels, FFR value, initial decision and final decision; and for analysis by 
ACS and deferral status: the same covariates than for analysis by ACS and reclassification status minus the final decision that was omitted. These analyses 
are using only using subjects with complete case of baseline covariate data.
‡Cox proportional hazards model controlling for baseline characteristics using multiple imputation method to impute missing baseline covariate data.
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was as safe in ACS (hazard ratio [HR] for MACE=0.63 [0.24–
1.71]; P=0.37) as in non-ACS (HR=0.94 [0.55–1.81]; P=0.82; 
Figure 5A), whereas FFR-based deferral of patients with ACS 
was associated with a similarly good outcome as in patients 
with non-ACS (HR for MACE in deferred non-ACS versus 
deferred ACS=0.91 [0.47–1.74]; P=0.77; Figure 5B).
Discussion
To our best knowledge, this is the largest prospective study 
ever to report on the use of FFR in patients with ACS undergo-
ing angiography and its impact on treatment decisions and on 
clinical outcomes. In the merged PRIME-FFR cohort, from 
the 1983 patients enrolled in 40 centers in 2 European coun-
tries (R3F and POST-IT studies),6,17 533 were identified as 
sustaining an ongoing or recent ACS (Figure 1). The key find-
ings of our study are (1) that the overall reclassification rate 
of patient management strategy is high in patients with ACS 
(38%) and similar to the one observed in non-ACS although 
the pattern of reclassification was different (Figure 3), (2) that 
integrating FFR information to reclassify patient management 
is safe in patients with ACS and that, in particular, FFR-based 
deferral to medical treatment is as safe in patients with ACS 
as it is in patients with non-ACS (Figures 4 and 5), (3) that 
the diagnostic value of FFR is preserved in patients in whom 
the culprit vessel is unambiguously investigated as reported 
in patients with single-vessel CAD, and (4) that disregarding 
the information derived from FFR is associated with a dire 
outcome in both groups, but more so in patients in ACS.
Change in Management Strategy in Patients With 
ACS
We demonstrated that patients with ACS and non-ACS had a 
similar overall high reclassification rate. However, the pat-
tern of change between management strategies was different. 
Patients with ACS were more likely to be reclassified into one 
of the revascularization strategies (PCI or CABG) and less 
likely than patients with non-ACS to move from revasculariza-
tion to medical therapy (Table 1; Figure 3B and 3C; Figure II in 
the Data Supplement). This finding may be the result of patients 
with ACS having a more complex disease profile, namely, with 
a higher proportion of B2/C lesions (Table 2). We reported pre-
viously that such B2/C lesions were predictive of lower FFR 
values, regardless of diameter stenosis severity.6 This was fur-
ther confirmed in the present data set, both in patients with ACS 
and in stable patients (Table II in the Data Supplement). The 
observation that within each category of stenosis severity, FFR 
was lower in more complex lesions (B2/C versus A/B1; Table I 
in the Data Supplement) was further supportive of this explana-
tion. The importance of lesion complexity is frequently under-
estimated when assessing lesion functional severity based on 
angio eyeballing alone, potentially making the operators more 
likely to consider for a priori medical therapy, a lesion that 
ended up warranting revascularization after FFR was known.
The present study also extends to the ACS population the 
previous observation from both the R3F6 and the POST-IT17 
studies that the routine integration of FFR on management 
decisions does not necessarily reduce the overall percentage 
of patients undergoing revascularization (namely, PCI), con-
trary to common belief.
Only one other study, the FAMOUS-NSTEMI trial 
(Fractional Flow Reserve Versus Angiography in Guiding 
Management to Optimize Outcomes in Non–ST-Elevation 
Myocardial Infarction), has evaluated the impact of FFR in 
management decisions of patients with ACS and found a lower 
reclassification rate of 21%.7 Reasons for this discrepancy 
may be several. However, it is likely related to the distribution 
of lesions within each study. In our cohort, the proportion of 
truly intermediate stenosis (50%–70%) that were interrogated 
was higher than in FAMOUS-NSTEMI; for these lesions, 
treatment change is more likely to occur. Conversely, in that 
landmark randomized trial,7 all lesions ≥30% (and not exclud-
ing the tightest ones) had to be interrogated per protocol, thus 
rendering the impact of FFR potentially less pronounced.
Integrating and Relying on FFR for Treatment 
Decision Is Safe in Patients With ACS
Our study clearly shows that not only is it safe to pursue a 
treatment strategy different from angiography but also not 
integrating FFR in the management workout is associated with 
an ominous clinical outcome. This was as true for patients 
Table 5. Clinical Outcomes at 12 Months by Management Strategy: Deferred Versus Nondeferred Patients
Analysis Group





ACS FFR used (n=499)
  ACS-deferred (n=237, 47%) 19 (8.0%) 12 (5.1%) 10 (4.2%) 3 (1.3%) 9 (3.8%)
  ACS-nondeferred (n=262, 53%) 32 (12.3%) 20 (7.7%) 13 (5.0%) 10 (3.8%) 17 (6.5%)
  P value (log rank) 0.09 0.25 0.70 0.09 0.19
Non-ACS FFR used (n=1353) 
  Non-ACS-deferred (n=721, 53%) 61 (8.5%) 24 (3.3%) 17 (2.4%) 7 (1.0%) 42 (5.9%)
  Non-ACS-nondeferred (n=632, 47%) 47%) 60 (9.5%) 18 (2.9%) 10 (1.6%) 9 (1.4%) 47 (7.4%)
  P value (log rank) 0.51 0.60 0.31 0.45 0.24
P value (ACS-deferred vs non-ACS deferred, log rank) 0.83 0.23 0.14 0.70 0.24
Data represented as count (%). ACS indicates acute coronary syndrome; deferred patients, all lesions deferred by FFR; FFR, fractional flow reserve; 
MACE, major cardiovascular event; MI, myocardial infarction; and Nondeferred patients, at least 1 lesion revascularized (percutaneous coronary 
intervention or coronary artery bypass grafting).
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with ACS as for patients with non-ACS , and actually the 
magnitude of the difference in the outcomes was even more 
pronounced in the ACS group. Indeed, despite patients with 
ACS having a higher coronary disease burden and complexity 
(Table 2), the rate of all end points was similar in reclassified, 
relative to nonreclassified patients (Table 3), meaning that 
Figure 4. Fractional flow reserve (FFR)–based decision and clinical outcome in the overall acute coronary syndrome (ACS) population. 
A, FFR-based reclassification of the patient coronary revascularization strategy in patients with ACS: impact on 1-y outcome. Patients 
with non-ACS are presented for comparison. FFR-based reclassification (FFR against angiography) was safe in patients with ACS (plain 
red line). B, Safety of FFR-based deferral to medical treatment in patients with ACS: impact on 1-y outcome. Patients with non-ACS are 
presented for comparison. FFR-based deferral to medical treatment was as safe in ACS (green line) as it was in non-ACS (blue line). HR 
indicates hazard ratio; and MACE, major cardiovascular event.
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Figure 5. Fractional flow reserve (FFR)–based decision and clinical outcome in patients with acute coronary syndrome (ACS) investigated 
at the culprit vessel (ACS patients with single-vessel coronary artery disease [CAD]). A, FFR-based reclassification of the patient coro-
nary revascularization strategy in ACS patients with single-vessel CAD: impact on 1-y outcome. Patients with non-ACS are presented for 
comparison. FFR-based reclassification (FFR against angiography) was safe in patients with ACS (plain red line). B, Safety of FFR-based 
deferral to medical treatment in ACS patients with single-vessel CAD: impact on 1-y outcome. Patients with non-ACS are presented for 
comparison. FFR-based deferral to medical treatment was as safe in ACS (green line) as it was in non-ACS (blue line).
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neither prognosis nor symptom status of patients with ACS 
were jeopardized when treated against angiography. This is 
an important addition to the results of the FAMOUS-NSTEMI 
randomized trial, which was not powered to assess for differ-
ences in clinical outcomes, and in which the specific clinical 
outcome of patients reclassified by FFR was not reported.7
Although there were no protocol-mandated recommenda-
tions as to what vessels should be evaluated and how to use 
the information derived from FFR, the majority of patients 
were treated according to the FFR result. In ≈6% of cases in 
both the ACS and non-ACS groups, FFR was disregarded for 
treatment decision. It is noteworthy that these patients were 
nearly twice as likely to experience adverse events during the 
12-month follow-up, both in the ACS and in the non-ACS 
cohorts (Table 4; Figure II in the Data Supplement). However, 
despite adequate statistical corrections for relevant baseline 
differences, it is still difficult to definitively exclude bias 
(related to unmeasured comorbidity such as patient frailty and 
lesion complexity) and claim causality. Nevertheless, a plau-
sible explanation for the worse outcome may rely on the fact 
that the majority of patients (67.9%) in whom FFR was disre-
garded for treatment decision had lesions with an FFR<0.80 
that were left untreated and that 60% of the reported events 
were actually unplanned revascularizations. This is line with 
the observations from both the FAME II trial (The Fractional 
Flow Reserve–Guided PCI Versus Medical Therapy in 
Stable Coronary Disease Study) and the POST-IT study.2,17 
Furthermore, it reinforces the importance of fully integrating 
FFR findings into treatment decisions, to minimize the risk of 
adverse clinical events.
Deferring Lesions Based on FFR in Patients With 
ACS Entails a Good Clinical Outcome
Demonstration of the safety of deferring a patient with ACS to 
medical treatment is another key finding of the present study. 
It is relevant that the incidence of the study composite primary 
end point at 12 months was similar in those patients with ACS 
and non-ACS in whom all lesions were deferred based on an 
FFR>0.80, and no revascularization was undertaken (Figure 5; 
Table 5). No dedicated randomized trial or subgroup analysis 
has specifically addressed the fate of lesions deferred in the 
context of ACS. A single-center retrospective study includ-
ing 334 patients with ACS over an 8-year period, observed 
an 8% increase in the risk of the composite end point of car-
diovascular death, MI, or differed lesion failure at 4.5±2.1 
years, per every 0.01 decrease in FFR, in deferred lesions with 
FFR>0.80. Importantly, in that study, the primary end point 
was mainly driven by ad hoc revascularization and not by MI 
or cardiovascular death related to the deferred lesions.21 In a 
subanalysis of the FAME-I study, the authors compared FFR-
guided versus angio-guided revascularization in 328 ACS 
versus all stable angina patients; they concluded that the risk 
difference favoring the FFR-guided approach was similar in 
both groups. However, despite the number of deferred lesions 
might have been intuitively higher in the FFR-guided group, 
there was no report on their specific outcome.15 Finally, in the 
recent DANAMI-3 PRIMULTI trial (the Third Danish Study 
of Optimal Acute Treatment of Patients With ST-Segment 
Elevation Myocardial Infarction; Primary PCI in Multivessel 
Disease), STEMI patients randomly allocated to FFR-guided 
revascularization of nonculprit lesions had a better clinical 
outcome when compared with those with no further invasive 
treatment. The authors reported that in the 97 patients whose 
revascularization was deferred based on an FFR>0.80, the out-
come did not differ from the remainder of the group, suggest-
ing that deferral is safe in this setting.14 Finally, in the recent 
COMPARE-ACUTE trial (Randomised Trial of FFR-Guided 
Complete Revascularization Versus Infarct Artery Only Treat-
ment in Multivessel STEMI  Patients), 1-year MACCE rate 
was the lowest in the subgroup of 134 STEMI patients whose 
nonculprit lesions (evaluated acutely during primary PCI) had 
a known FFR>0.80.22 Overall, our results reinforce the poten-
tial role of FFR in this setting and demonstrate that in patients 
diagnosed with an ACS, in whom operators feel that FFR is 
appropriate for decision making, an FFR value of >0.80 in all 
investigated lesions reliably identifies a group of patients at 
a lower risk of events (when compared to those were PCI or 
CABG is deemed necessary by FFR) and indicates that revas-
cularization can be safely deferred (Figure 5; Table 5).
Role of Time and Reliability of FFR at Culprit 
Vessel in Patients With ACS
Two important findings of the present study are the demon-
stration of the safety of FFR-based reclassification and FFR-
based deferral in patients with ongoing NSTEM/UA and in 
patients in whom FFR was performed at the culprit vessel. 
In the context of NSTEMI/UA, there is no definitive way to 
fully determine whether FFR is being performed at the cul-
prit vessel or not, at the noticeable exception of patients with 
ACS with single-vessel disease.13 This is why, as performed 
by Layland et al,13 it was key to specifically investigate the 
subgroup of patients with single-vessel disease ACS and to 
demonstrate that the safety of the FFR-based management 
was preserved in these patients.
Our findings are important because the reliability of FFR 
to guide management decisions in patients with ACS has been 
challenged by the potential for microcirculatory hyporespon-
siveness that has been observed within the first days of the 
acute event. In addition, patients with ACS frequently have 
>1 lesion suitable for revascularization and the identification 
of the culprit lesion is not always straightforward, particularly 
when stenosis are intermediate at angiography. Also, the coex-
istence of multiple lesions with features of instability is a com-
mon finding in patients with ACS.23 Thus, the issue of whether 
FFR values (and subsequent decisions) are reliable, irrespec-
tive of the timing of investigation and of whether the culprit 
lesion is known for certain, are of major clinical importance. 
Available clinical evidence on these issues is both relatively 
scarce and conflicting. Niccoli et al24 measured coronary flow 
and pressure in nonculprit lesions of 15 patients with NSTEMI 
and compared it with 15 patients with stable angina. They 
concluded that, relative to their stable counterparts, patients 
with ACS were more likely to have both higher baseline and 
lower reductions in hyperemic myocardial resistance, leading 
to a higher FFR, in discordance to hyperemic stenosis resis-
tance for any given lesion. In the study by Ntalianis et al,12 
similarly investigating the reliability of FFR measurement in 
nonculprit lesions in a larger cohort of 101 patients with ACS, 
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there was no difference on average FFR measured acutely, as 
compared with that evaluated at 35±4 days (0.77±0.13 versus 
0.77±0.13), and in only 2 patients, the FFR value was higher 
than 0.8 during the acute phase and lower than 0.75 at follow-
up. However, despite the authors did not specifically report on 
the actual proportion of cases, some variation occurred around 
the 0.80 cutoff (in both directions). Layland et al13 investigated 
resistive reserve and microcirculatory resistance of the culprit 
vessels in 50 patients with NSTEMI. In that study, the cul-
prit status of the vessel was elegantly ascertained by including 
only patients with single-vessel CAD. They could demon-
strate that, in NSTEMI patients, the vasodilatory capacity of 
the microcirculation of the culprit vessel was preserved and 
similar to stable angina patients. Another study investigated 
microcirculatory resistance (using CRF and index of micro-
circulatory resistance) and pressure gradients (resting Pd/
Pa and FFR) in the culprit vessel of STEMI patients under-
going primary PCI and then subsequently at 24 hours and 6 
months. FFR at the culprit vessel was lower overtime, but only 
in those with microvascular obstruction on cardiac magnetic 
resonance at baseline.25 Overall, these results suggest that in 
patients with non–ST-segment–elevation ACS, microvascular 
dysfunction may be less marked, and the ability to achieve 
hyperemia likely is sufficient to maintain the diagnostic use 
of FFR, both in culprit and in nonculprit vessels. Importantly, 
the results of our study build on those previous observations 
by providing information on clinical outcome and by demon-
strating the safety of FFR-based management in patients with 
ACS, including those with ongoing NSTEMI/UA and those in 
whom the culprit vessel was explored by FFR.
Study Limitations
The present study is the combination of 2 nationwide pro-
spective FFR studies, and we cannot exclude that unmeasured 
differences between the 2 cohorts might have influenced our 
findings. However, the previous published results of R3F6 and 
POST-IT17 as well as the outcome analyses performed sepa-
rately in each data set demonstrated consistency between the 
2 cohorts.
As the current study included patients with ACS mostly 
with intermediate coronary lesion(s), in whom the extensive-
ness of FFR investigation was left to physician’s choice, we 
cannot exclude that this represents a lower risk subset of ACS. 
However, several evidences are reassuring in this respect. 
First, in the PRIME-FFR cohort (regardless of FFR findings 
and FFR-based decision), event rates (especially death/MI) in 
the ACS subgroup were higher than in patients with non-ACS, 
reflecting indeed a higher risk. Second, death/MI rates of the 
PRIME-FFR ACS population are within the range of previous 
reports, such as the FAMOUS-NSTEMI7 study and the ACS 
subset of the FAME-I trial.15 Furthermore, the baseline clini-
cal profile of our patients with ACS was clearly worse than 
in the FAMOUS-NSTEMI population and comparable to the 
ACS subset of the FAME-I trial.7,15
In addition, as the present study did not include any 
patients with an acute STEMI, it should be acknowledged that 
our findings do not apply to this population.
Given its observational nature, we cannot rule out uncon-
trolled confounding by additional factors. However, despite its 
nonrandomized nature, the relevance of our findings should not 
be downplayed. In the setting of randomized trials, the com-
bination of protocol-mandated procedures and highly selec-
tive inclusion and exclusion criteria frequently narrows their 
applicability to daily real-word practice.26,27 In the particular 
case of the present prospective study, we were able to expand 
to a specific population with ACS the findings from previous 
nonrandomized prospective studies, such as the RIPCORD 
study (Does Routine Pressure Wire Assessment Influence 
Management Strategy at Coronary Angiography for Diagnosis 
of Chest Pain), the R3F, and the POST-IT studies, namely, the 
potential of routine use of FFR for management reclassifica-
tion and the safety of lesion deferral. These findings were fur-
ther supported by extensive multivariable analyses.
Finally, the present study included mostly patients with 
truly intermediate lesions in whom the likelihood of reclassi-
fication by FFR is expected to be at its highest. Therefore, our 
results may not extend to patients with angiographically severe 
multivessel disease and tight lesions, as those investigated in 
the recently reported randomized FUTURE study (Fractional 
Flow Reserve for Guiding Treatment Strategy in Multivessel 
Disease Patients),28 which also included a significant portion 
of patients with ACS (46%). In FUTURE, although >90% of 
patients were considered for revascularization as based on angi-
ography alone (as compared with 41% in the present PRIME-
FFR), the reclassification rate was only 8% (as compared with 
the 38% observed in PRIME-FFR). As mentioned earlier, 
this could be related to a higher lesion severity (mean FFR of 
0.77 as compared with 0.82 in PRIME-FFR) and explain why 
a clinical benefit of reclassification was not observed in the 
FUTURE study.28 We must, however, be extremely cautious 
in interpreting the initial report of the FUTURE study as the 
clinical follow-up is not complete (85% of the total population 
reported only) and as the article is not available.
Conclusions
In patients with ACS undergoing a coronary angiography, 
routine use of FFR is associated with a high rate of reclas-
sification (38%) of clinical management. A strategy guided by 
FFR, divergent from that suggested by angiography, including 
revascularization deferral, seems to be safe in these patients. 
Furthermore, this study extends to the ACS population, the 
previous observation made in the general populations of R3F, 
RIPCORD, and POST-IT,5,6,17 that the ultimate effect of routine 
FFR at time of angiography is not to decrease the number of 
patients referred to revascularization, but rather to deliver the 
appropriate treatment to each individual patient.26,27 However, 
large randomized trials, powered for clinical outcomes, are 
needed to further refine the role of FFR and of new physiolog-
ical indexes, independent of inducible hyperemia, on patient 
management in this setting. Both the DEFINE-FLAIR29 (Use 
of the Instantaneous Wave-Free Ratio or Fractional Flow 
Reserve in PCI) and iFR-SWEDEHEART30 (Evaluation of 
iFR vs FFR in Stable Angina or Acute Coronary Syndrome) 
randomized studies—which compared FFR- with iFR-guided 
treatment of obstructive CAD—have included ≈20% and 38% 
of patients with ACS, respectively. Although no specific sub-
group analysis is yet available, it will likely provide additional 
clarification on the subject.
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Patient definition and recording of baseline characteristics 
 
Hypertension was defined as a known blood pressure >140/90 mmHg or use of antihypertensive drugs. 
Smoking was defined as acknowledged ceased/unceased smoking. Diabetes mellitus was defined as a fasting 
glucose ≥126mg/dL, use of hypoglycaemic agents, or a history of physician-diagnosed diabetes mellitus. 
Family history of premature CAD was defined as CAD in a male first-degree relative <55 years old or CAD in 




In each study an independent Clinical Research Associate was hired for data monitoring purposes. In each 
centre, a minimal number of cases (n=20 in POST-ITt and n=25 in R3F) and a minimal percent of all cases 
(20% in Post-It and 25% in R3F) were reviewed. In centers including a small number of patients (centers 
with n≤20 in Post-it; n≤25 in R3F) and every time it was considered appropriate following the initial sampling 
review, a review of all cases of the center was performed. Monitoring included protocol compliance, as well 




The Cox Proportional Hazards analyses were performed using three different methods.  The first model 
evaluates event rates without adjusting for relevant baseline covariates.  The second model uses an 
adjustment for baseline covariates but does so on a complete case basis.  The third analysis adjusts for 
baseline covariates and utilizes multiple imputation to impute missing covariate data. 
 
Baseline covariates were selected based on statistical significance (p<0.10) of demographics, clinical risk 
factors, and prior clinical history when comparing ACS patients to Non-ACS patients in the FFR Used 
Population.  These variables included age, diabetes, hypertension, high cholesterol, previous myocardial 
infarction, previous CABG, and number of diseased vessels >50%.  Previous MI and previous CABG both had 
a high degree of missing data (>20%) which may have contributed to statistical significance and were 
determined to not be missing at random.  The final set of covariates entering the model were age, gender, 
diabetes, hypertension, high cholesterol, and number of diseased vessels >50%.  Gender was added to the 
covariate list due to its clinical importance and use in the analyses performed in R3F and POST-IT studies. 
 
Due to missing data in some covariates, the complete case covariate adjusted model has limitations because 
only subjects with complete event and covariates data are included in the model.  In order to evaluate all 
patients adjusted by baseline covariates, the missing covariate data can be imputed.1 The total amount of 
covariate missing data was small and represents 1.3% of all covariate data points with a maximum of 2.9% 
4 
 
per variable.  After examining the quantity of missing values and potential patterns in missing values, it was 
determined that missing values in these covariates were missing at random (MAR). 
 
Covariate data were imputed using standard multiple imputation modeling with a discriminant function.2 An 
N of ten imputed datasets was created for each Cox Proportional Hazards analysis.  The Cox model was then 
applied to each of the ten datasets, creating ten separate results per analysis.  The final results were generated 
by pooling the estimates of the individual proportional hazards, accounting for the standard error within and 






Supplemental Table 1. FFR value by range of % stenosis severity, angiographic complexity and ACS 
status.   
 
  
    FFR value  
Group 
Stenosis 
Severity Complexity N Mean StdDev StdErr 
p-
value1 
ACS Population 0-49% B2/C 36 0.841 0.099 0.016 0.327 
A/B1 82 0.862 0.074 0.008 
50-69% B2/C 178 0.815 0.087 0.007 <.001 
A/B1 257 0.841 0.087 0.005 
70-89% B2/C 87 0.750 0.088 0.009 0.012 
A/B1 63 0.790 0.120 0.015 
≥90% B2/C 9 0.675 0.136 0.045 0.793 
A/B1 5 0.716 0.102 0.046 
Non-ACS Population 0-49% B2/C 138 0.827 0.094 0.008 <.001 
A/B1 366 0.864 0.074 0.004 
50-69% B2/C 421 0.807 0.098 0.005 <.001 
A/B1 658 0.843 0.083 0.003 
70-89% B2/C 172 0.734 0.117 0.009 0.001 
A/B1 171 0.769 0.102 0.008 
≥90% B2/C 26 0.644 0.118 0.023 0.341 
A/B1 25 0.672 0.142 0.028 
Total Population 0-49% B2/C 174 0.830 0.095 0.007 <.001 
A/B1 448 0.864 0.074 0.003 
50-69% B2/C 599 0.809 0.095 0.004 <.001 
A/B1 915 0.842 0.084 0.003 
70-89% B2/C 259 0.739 0.108 0.007 <.001 
A/B1 234 0.775 0.107 0.007 
≥90% B2/C 35 0.652 0.121 0.020 0.392 
A/B1 30 0.680 0.136 0.025 











Predictors of a lower FFR 








ACC/AHA Classification B2/C 0.016 0.005 0.001   0.020 0.008 0.014 
Age (years) -0.001 0.000 <.001   -0.001 0.000 0.002 
Any proximal lesion -0.006 0.005 0.173   -0.003 0.008 0.710 
Diabetes mellitus 0.005 0.005 0.263   0.003 0.008 0.717 
LAD location 0.049 0.004 <.001   0.051 0.008 <.001 
LVEF <=50% 0.012 0.006 0.045   0.005 0.010 0.599 
Lesion - % stenosis 0.002 0.000 <.001   0.002 0.000 <.001 
Lesion - Length (mm) 0.003 0.000 <.001   0.002 0.001 0.002 
Male Gender 0.012 0.005 0.023   -0.009 0.009 0.346 
Number of diseased vessels by 
angiography 
   
     
1 Diseased Vessel 0.016 0.006 0.013   0.023 0.012 0.050 
2 Diseased Vessels 0.042 0.007 <.001   0.031 0.013 0.018 
3 Diseased Vessels 0.047 0.008 <.001   0.045 0.014 0.001 








Supplemental Table 3. Patient’s baseline characteristics by ”deferral” and ACS status (in patients in 
which FFR was used) 
 
 
1 p-values comparing ACS: All Lesions Deferred vs. Lesions Treated;   
2 p-values comparing Non-ACS: All Lesions Deferred vs. Lesions Treated; 
3 p-values comparing All Lesions Deferred: ACS vs. Non-ACS; 
4 p-values comparing Lesions Treated: ACS vs. Non-ACS; 
*Wilcoxon Rank-sum test used for continuous variables and Chi-Square test used for categorical variables. 
Ϯ Current or former smoker <1 year 
 
 ACS  Non-ACS 















Age (years) 66.0±11.2 62.1±11.7  66.4±10.0 64.0±10.0 <.001 <.001 0.640 0.011 
Male Gender 169 (71.3%) 204 (77.9%)  524 (72.7%) 506 (80.1%) 0.092 0.001 0.683 0.459 
 
Cardiovascular risk factors 
Diabetes mellitus 61 (26.5%) 87 (34.0%)  235 (33.6%) 270 (43.5%) 0.074 <.001 0.046 0.009 
Hypertension 168 (73.0%) 177 (69.1%)  540 (77.1%) 462 (74.4%) 0.344 0.244 0.206 0.112 
Smoking Ϯ 93 (39.2%) 126 (48.1%)  271 (37.6%) 257 (40.7%) 0.113 0.428 0.880 0.073 
High Cholesterol 148 (64.6%) 166 (65.4%)  513 (73.4%) 457 (73.8%) 0.867 0.857 0.011 0.012 
 
Prior clinical history 
Myocardial infarction 84 (47.5%) 90 (41.9%)  163 (28.7%) 169 (32.9%) 0.267 0.131 <.001 0.022 
PCI 85 (48.0%) 97 (45.1%)  270 (47.5%) 225 (43.9%) 0.566 0.236 0.894 0.755 
CABG 4 (2.3%) 6 (2.8%)  35 (6.2%) 17 (3.3%) 0.740 0.029 0.042 0.713 
          
LVEF <=50% 36 (15.2%) 43 (16.4%)  109 (15.1%) 122 (19.3%) 0.107 0.008 0.778 0.597 
Cardiovascular medication         
Dual anti-platelet 139 (59.4%) 153 (60.2%)  354 (49.6%) 340 (54.2%) 0.851 0.089 0.009 0.104 
Statine 177 (75.6%) 193 (76.0%)  542 (76.0%) 498 (79.7%) 0.930 0.108 0.907 0.226 
ACEI/ARB 154 (66.4%) 145 (58.9%)  416 (58.6%) 367 (59.1%) 0.093 0.851 0.035 0.967 
Beta-Blockers 137 (59.1%) 155 (62.0%)  427 (59.9%) 390 (62.9%) 0.508 0.260 0.822 0.803 
          
Number of diseased vessels (>50%) 
0 58 (24.5%) 13 (5.0%)  228 (31.6%) 31 (4.9%) 
<.001 <.001 0.080 0.985 
1 100 (42.2%) 98 (37.4%)  307 (42.6%) 235 (37.2%) 
2 56 (23.6%) 88 (33.6%)  130 (18.0%) 220 (34.8%) 
3 23 (9.7%) 63 (24.0%)  56 (7.8%) 146 (23.1%) 
Number of lesions evaluated 
1 194 (81.9%) 181 (69.1%)  577 (80.0%) 426 (67.4%) 
0.010 <.001 0.470 0.970 2 30 (12.7%) 60 (22.9%)  116 (16.1%) 153 (24.2%) 
≥3 13 (5.4%) 21 (8.0%)  28 (3.9%) 53 (8.4%) 
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Supplemental Table 4.  Lesion’s baseline angiographic and FFR characteristics by ”deferral” and ACS status 
 
 
1 p-values comparing ACS: All Lesions Deferred vs. Lesions Treated 
2 p-values comparing Non-ACS: All Lesions Deferred vs. Lesions Treated 
3 p-values comparing All Lesions Deferred: ACS vs. Non-ACS 
4 p-values comparing Lesions Treated: ACS vs. Non-ACS 
*Wilcoxon Rank-sum test used for continuous variables and Chi-Square test used for categorical variables.
 ACS   Non-ACS 
p-value1 p-value2 p-value3 p-value4 
 








Lesion location           
Left Anterior Descending 144 (49.7%) 237 (64.1%)   469 (52.3%) 575 (63.3%) 0.006 <.001 0.038 0.351 
Circumflex 69 (23.8%) 62 (16.8%)   144 (16.1%) 122 (13.4%)     
Right Coronary Artery 63 (21.7%) 54 (14.6%)   221 (24.6%) 156 (17.2%)     
Left Main 13 (4.5%) 16 (4.3%)   56 (6.2%) 49 (5.4%)     
Bypass 1 (0.3%) 1 (0.3%)   7 (0.8%) 6 (0.7%)     
Proximal LAD 47 (16.2%) 65 (17.6%)   151 (16.8%) 201 (22.1%) 0.644 0.004 0.803 0.068 
Any proximal lesion 101 (34.8%) 118 (31.9%)   311 (34.7%) 317 (34.9%) 0.427 0.914 0.961 0.301 
Lesion - % stenosis 53.6±10.7 60.6±13.0   50.5±11.7 59.6±14.2 <.001 <.001 <.001 0.205 
Stenosis Severity           
0-49% 69 (23.8%) 41 (11.1%)   306 (34.1%) 169 (18.6%) <.001 <.001 0.002 0.010 
50-69% 187 (64.5%) 210 (56.8%)   527 (58.8%) 463 (51.0%)     
70-89% 34 (11.7%) 105 (28.4%)   63 (7.0%) 237 (26.1%)     
≥90% 0 (0.0%) 14 (3.8%)   1 (0.1%) 39 (4.3%)     
  ACC/AHA Classification B2/C 94 (32.4%) 187 (50.5%)   245 (27.3%) 428 (47.1%) <.001 <.001 0.097 0.269 
  Vessel Reference Diameter (mm) 3.04±0.53 2.93±0.52   2.96±0.56 2.87±0.52 0.016 <.001 0.032 0.038 
  Lesion - Length (mm) 12.0±5.5 15.0±7.9   11.7±5.9 15.1±8.5 <.001 <.001 0.480 0.748 
FFR (all lesions) 0.89±0.05 0.76±0.10   0.89±0.05 0.76±0.10 <.001 <.001 0.649 0.166 
Lesions with FFR ≤ 0.80 6 (2.1%) 254 (68.6%)   5 (0.6%) 676 (74.4%) <.001 <.001 0.020 0.035 
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Supplemental Table 5. Sub-group analysis: 1-year outcome according to reclassification status (A) and 
management strategy (B) in ongoing ACS vs. recent ACS. 
 
 
ACS Group Strategy Change N (%) p-value MACE p-value 
A. Reclassification status 
Ongoing ACS  213  19 (8.9%)  
 Reclassified 74 (35%)  6 (8.1%)  
 Non-reclassified 139 (65%) 0.31 1 13 (9.4%) 0.52 2 
Recent ACS  285  32 (11.2%)  










B. Management strategy 
Ongoing ACS  213  19 (8.9%)  
 All lesions deferred 98 (32%)  6 (6.1%)  
 At least 1 revascularized 115 (54%) 0.52 3 13 (11.3%) 0.62 4 
Recent ACS  285  32 (11.2%)  
 All lesions deferred 139 (49%)  13 (9.4%)  
 










1 p-value for the comparison of reclassification status in Ongoing ACS vs. Other ACS   
2 p-value for the interaction of ACS Type and Reclassification Status on MACE outcome 
3 p-value for the comparison of Management Strategy in Ongoing ACS vs. Other ACS   







Supplemental Table 6. Sub-group analysis: 1-year outcome according to reclassification status (A) and 




Diseased vessel group Strategy Change N (%) p-value MACE p-value 
A. Reclassification status 
Multi-vessel-CAD  229  28 (12.2%)  
 Reclassified 107 (47%)  10 (9.3%)  
 Non-reclassified 122 (53%) <0.001 1 18 (14.8%) 0.97 2 
Single-vessel-CAD  269  23 (8.6%)  




189 (70%)  18 (9.5%)  
B. Management strategy 
Multi-vessel-CAD  229  28 (12.2%)  
 All lesions deferred 79 (34%)  7 (8.9%)  
 At least 1 revascularized 150 (66%) <0.001 3 21 (14.0%) 0.76 4 
Single-vessel-CAD  269  23 (8.6%)  
 All lesions deferred 158 (59%)  12 (7.6%)  
 
At least 1 revascularized 
 
111 (41%)  11 (9.9%)  
 
1 p-value for the comparison of reclassification status in in >1 Diseased Vessels (>50%) vs. ≤1 Diseased Vessel 
2 p-value for the interaction of Vessel Disease and Reclassification Status on MACE outcome 
3 p-value for the comparison of Management Strategy in >1 Diseased Vessels (>50%) vs. ≤1 Diseased Vessel 
















































Supplemental Figure 3. One-year outcome according to reclassification status and initial revascularization 
strategy in ACS (A) and in non-ACS patients (B)  
 
A – ACS patients 
 
 





































Supplemental Figure legends 
 
 




Supplemental Figure 2: Initial and Final Revascularization strategy in ACS and non-ACS patients.  Before the 
results of the FFR was known, the initial strategy was similar between ACS- and non-ACS patients. After FFR was 
known (final decision), the proportion of patients submitted to PCI or CABG was higher in the ACS-group, as 
compared to non-ACS (p=0.02). 
 
 
Supplemental Figure 3; One-year outcome according to reclassification status and initial revascularization 
strategy in ACS (A) and in non-ACS patients (B). For this illustration 4 groups were considered: Group 1: 
Revascularization (PCI or CABG) as initial strategy and medical treatment as final strategy; Group 2: 
Revascularization (PCI or CABG) as initial strategy and revascularization (PCI or CABG) as final strategy; Group 
3: Medical treatment as initial strategy and medical treatment as final strategy; and Group 4: Medical treatment 
as initial strategy and revascularization (PCI or CABG) as final strategy. 
 
 
Supplemental Figure 4: One-year outcome according to FFR use vs. “disregarded” in ACS and in non-ACS 
patients. In both ACS (red lines) and non-acs patients (blue lines), the rate of MACE at 1 year was two-fold higher 
in patients in patients in whom the FFR was disregarded (dashed lines) as compared to those in whom the FFR 
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